Cardiovascular, Liver, and other Organ Systems
Angel Baldan, Ph.D.
The Angel Baldan laboratory is interested in sterol homeostasis and in the molecular mechanisms involved in the conversion of macrophages into foam cells. This latter process is particularly relevant in several human pathologies, including atherosclerosis and different pulmonary lipidosis syndromes.
Keywords:Atherosclerosis, Pulmonary Lipidosis
Yi-Hwa Chang, Ph.D
Yi-Hwa Chang studies how two distinct methionine aminopeptidases (MetAPs) function in the amino-terminal processing of proteins and its role in blood vessel formation (angiogenesis), which plays a vital role in both healthy and disease states. Recently, the type-2 MetAP was found to be the target of angiogenesis inhibitors TNP-470 and ovalicin. He has also developed molecular sensors for detection of proteins and DNA binding suitable for High-Throughput screening.
Keywords:Angiogenesis, High-throughput Assays
David Ford, Ph.D.
David Ford has pioneered the field of lipidomics to study mechanisms responsible for cardiovascular diseases. He combines expertise in physiological models of diseases with mass spectrometry and bio-organic techniques to interrogate alterations in lipid metabolism and signaling pathways involved with cardiovascular disease. He also applies these lipidomics techniques to collaborator studies including infectious diseases and vaccines.
Keywords:Cardiovascular Disease, Mass Spectroscopy, Lung Injury and Biology
Kyle McCommis, Ph.D.
Kyle McCommis is an expert in the role of mitochondrial metabolism in health and disease. One project studies the connection between heart failure and altered hepatic metabolism via liver ketone body production. Another project studies mitochondrial metabolism during activation of hepatic stellate cells and their role in liver fibrosis. This research may lead to treatments reducing hepatic fibrosis through inhibition of mitochondrial metabolism.
Keywords:Liver Fibrosis, Heart Failure, Hepatic Metabolism
John Tavis, Ph.D.
John Tavis studies the role of viral RNaseH in promoting viral infection and replication, with a focus on studying Hepatitis B. John has translated his work into the discovery of novel molecules for treatment of HBV which has been licensed to Casterbridge pharmaceuticals which he helped found. He has also advised other companies on the development of in vitro and in vivo viral infection models for drug discovery.
Keywords:Hepatitis, Retroviral Treatment, Small Molecule Screening
David Griggs, Ph.D
David Griggs applies his medicinal chemistry expertise across a wide range of collaborative translational efforts in organ fibrosis, bone disorders, and infectious diseases. He is an expert in target validation, assay development (HTS), and lead optimization through both in vitro and in vivo pharmacokinetics. Some of his own discoveries on integrins and organ fibrosis have been licensesed to Indalo Therapeutics, which he helped found.
Keywords:Organ Fibrosis, Tuberculosis, High-throughput Assays